The aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .
Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments. One new treatment approach uses umbilical cord blood derived mesenchymal stem cells-specialized cells capable of developing into other types of cells-to stimulate growth of new blood vessels for the heart. The aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Procedure: Selected patients were randomly divided into a cell therapy group and a control group. Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.
the First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The examination of heart function
Left ventricular ejection fraction: Change in left ventricular ejection fraction assessed with echocardiography after intramyocardial implantation of allogeneic mesenchymal stem cells.
Time frame: Post cell transplantation: 1, 3, 6 months
all-cause mortality
Time frame: Post cell transplantation: one year
all-cause morbidity
Time frame: Post cell transplantation: one year
major adverse cardiac and cerebrovascular events
Time frame: Post cell transplantation: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.